PF 06840003

Drug Profile

PF 06840003

Alternative Names: PF-06840003

Latest Information Update: 28 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antineoplastics
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioma

Most Recent Events

  • 01 Sep 2016 Phase-I clinical trials in Glioma in USA (PO) (NCT02764151)
  • 03 May 2016 Pfizer plans a first-in-patient phase I trial for Glioma (Late-stage disease, Recurrent) in USA (PO) (NCT02764151)
  • 16 Apr 2016 Preclinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top